EMA Refused: Milnacipran Pierre Fabre Medicament (milnacipran) — Pierre Fabre Medicament

View source ↗

Summary

EMA has refused the marketing authorization for Milnacipran Pierre Fabre Medicament for fibromyalgia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibromyalgia

Drugs mentioned

• Milnacipran Pierre Fabre Medicament (milnacipran)

Snippet

Status: Refused. Therapeutic area: Fibromyalgia. MAH: Pierre Fabre Medicament. Decision date: 26/04/2010